Drug intelligence / Profile preview

Omicron Inactivated COVID-19 Vaccine (Vero Cell)

Development stage
Phase 3
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The **Omicron Inactivated COVID-19 Vaccine (Vero Cell)** is an inactivated vaccine developed to protect against COVID-19 caused by the Omicron variant of SARS-CoV-2. It uses whole virions of the Omicron strain propagated in Vero cells—a continuous cell line derived from African green monkey kidney cells—then inactivated (typically with beta-propiolactone or formaldehyde) to preserve key antigens while eliminating infectivity. The mechanism involves intramuscular injection to induce neutralizing antibodies and T-cell responses targeting the SARS-CoV-2 spike protein and other viral components, mimicking natural infection without causing disease. Primarily indicated for active immunization against symptomatic COVID-19 in adults and children, it was authorized in several countries including China, Indonesia, and others for booster use against Omicron subvariants.

Other names
omicron covid-19 vaccine (vero cell), inactivatedcovid-19 vaccine, inactivated, omicron strainsars-cov-2 antigen inhibitors drug (sinovac biotech)
02

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Omicron Inactivated COVID-19 Vaccine (Vero Cell).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Omicron Inactivated COVID-19 Vaccine (Vero Cell).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call